Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
IPO Year:
Exchange: NASDAQ
Website: rezolutebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $12.00 | Outperform | Wedbush |
| 8/27/2024 | $11.00 | Buy | Guggenheim |
| 7/17/2024 | $13.00 | Buy | BTIG Research |
| 6/4/2024 | $14.00 | Buy | Craig Hallum |
| 4/9/2024 | $8.00 | Buy | Maxim Group |
| 8/2/2022 | $17.00 | Buy | Canaccord Genuity |
| 6/15/2022 | $9.00 | Overweight | Cantor Fitzgerald |
| 11/29/2021 | $30.00 → $17.00 | Buy | Canaccord Genuity |
| 11/15/2021 | $30.00 → $18.00 | Market Outperform | JMP Securities |
| 9/8/2021 | $21.00 | Buy | ROTH Capital |
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the "Inducement Grant"). About Mr. Evans "This is a pivotal year for Rezolute as we initiated our Phase 3 clinical study for RZ358 in congenital hyperinsulinism and anticipate reporting topline data from our Phase 2 study for RZ402 in diabetic macular edema in the secon
REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that the Company has initiated dosing in a Phase 1b multiple-ascending dose study of RZ402, Rezolute's investigational oral plasma kallikrein inhibitor (PKI) for the treatment of diabetic macular edema (DME). Rezolute also announced the appointment of ophthalmology expert and key opinion leader, Dr. Rajat Agrawal, MD, MS, as Vice President, Clinical Development to lead the RZ402 clinical development program. "The Phase 1b study will evaluate the
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the addition of Davelyn Hood, MD, to its leadership team as Director, Scientific and Patient Affairs. In her new role, Dr. Hood will be a key member of the team in furthering the development of RZ358, Rezolute's monoclonal antibody currently being evaluated in a Phase 2b clinical trial to treat congenital hyperinsulinism, a rare disease that is the most common cause of persistent low blood sugars in children. "Dr. Hood is an ideal addition to our
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose imbalance, today announced the addition of Quan Dong Nguyen, MD, MSc, FAAO, FARVO to its Scientific Advisory Board. Dr. Nguyen is a renowned expert in retinal vascular and uveitic diseases and is expected to provide valuable strategic and scientific counsel related to RZ402, the Company's investigational oral plasma kallikrein inhibitor (PKI), for the treatment of diabetic macular edema (DME). "Dr. Quan Dong Nguyen has a distinguished track record of innovative research leading to new treatments f
REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of IssuerDirect as the Company’s registrar and transfer agent and shareholder support provider. IssuerDirect will now be responsible for all transfers of Rezolute shares rather than VStock Transfer, LLC. Shareholders need take no action related to this transaction. About Rezolute, Inc.Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for congenital HI, a rare pediatri